CN3 PHARMACOECONOMIC (PE) ANALYSIS OF THE TREATMENT OF...

CN3 PHARMACOECONOMIC (PE) ANALYSIS OF THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE NETHERLANDS DEMONSTRATES THAT ERLOTINIB DOMINATES DOCETAXEL AND IS COST-EFFECTIVE OVER BEST SUPPORTIVE CARE (BSC) WITHOUT NEED FOR PATIENT STRATIFICATION

M Pompen, A Novak, P Postmus, M Gok, M Gyldmark
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
9
Year:
2006
Language:
english
DOI:
10.1016/s1098-3015(10)63205-6
File:
PDF, 67 KB
english, 2006
Conversion to is in progress
Conversion to is failed